Predicting Relapse after Cessation of Lamivudine Monotherapy for Chronic Hepatitis B Virus Infection

Clinical Infectious Diseases

Volumn 38, Issue 4, 2004, Pages 490-495

  Ito, Kiyoaki ^a,b   Tanaka, Yasuhito ^b   Orito, Etsuro ^b   Hirashima, Noboru ^a   Ide, Tatsuya ^d   Hino, Teruko ^d   Kumashiro, Ryukichi ^d   Kato, Atunaga ^a   Nukaya, Haruhiko ^a   Sakakibara, Kenji ^a   Mukaide, Motokazu ^e   Ito, Hidemi ^c   Sata, Michio ^d   Ueda, Ryuzo ^b   Mizokami, Masashi ^b  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e SRL INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; SEROCONVERSION; TREATMENT OUTCOME;

ADULT; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 10744232412     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/380965     Document Type: Article

References (28)

1. World Health Organization fact sheet/204. Hepatitis B. Geneva: World Health Organization, 2000.
2. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17:643-50.
3. Los AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2002; 122:2092-3.
4. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27:1711-6.
5. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119:172-80.
6. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32:828-34.
7. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847-51.
8. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567-72.
9. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27:1670-7.
10. Honkoop P, de Man RA, Niesters HG, Schalm SW. Clinical impact of lamivudine resistance in chronic hepatitis B. J Hepatol 1998; 29:510-1.
11. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003; 38(Suppl 1):S90-S103.
12. Mukaide M, Tanaka Y, Katayose S, et al. Development of real-time detection direct test for hepatitis B virus and comparison with two commercial tests using the WHO international standard. J Gastroenterol Hepatol 2003; 18:1264-71.
13. Pichoud C, Berby F, Stuyver L, Petit MA, Trepo C, Zoulim F. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. J Hepatol 2000; 32:307-16.
14. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002; 9:208-12.
15. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37:748-55.
16. Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol 2002; 17:409-14.
17. Liaw YF. Management of patients with chronic hepatitis B. J Gastroenterol Hepatol 2002; 17:406-8.
18. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-63.
19. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30:1082-7.
20. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie A, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114:629-34.
21. Wong DKH, Cheung AM, O'Rourke K, Naylor D, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: meta-analysis. Ann Intern Med 1993; 119:312-23.
22. Niederau C, Heintsges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334:1422-7.
23. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroentrology 1997; 113:1660-7.
24. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effects of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29:971-5.
25. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32:803-6.
26. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-8.
27. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30:770-4.
28. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33:998-1002.